Approval · Notice of Compliance 24682 · 2020
BLEXTEN: Notice of Compliance 24682
Issued November 25, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 24682
- Date
- November 25, 2020
- Company
- Aralez Pharmaceuticals Canada Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update the product labels for blexten to align with the current plain language labelling regulations
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BLEXTEN | Not yet assigned | — |
Medicinal ingredients
- BILASTINE 20 MG per TAB